ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Myriad Genetics Inc

Myriad Genetics Inc (MYGN)

5,83
-0,27
(-4,43%)
Geschlossen 12 Juli 10:00PM
5,81
-0,02
(-0,34%)
Nach Börsenschluss: 1:59AM

Myriad Genetics Inc (MYGN) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
5,83
( -4,43% )
Gebot
5,53
Fragen
6,10
Volumen
857.004
Durchschnittliches Volumen (3 Mio.)
US$ 1.647.328
Finanzvolumen
US$ 5.045.799
5,73 Tagesbereich 6,12
3,53 52-Wochen-Bereich 8,59
Marktkapitalisierung
Unternehmenswert
641,511M
Handelsende
6,10
Handelsbeginn
6,12
Letzte Trade
1
@
5.83
Letzter Handelszeitpunkt
VWAP
5,8877
Erlöse (LTM)
829M
Nettogewinn (LTM)
-399,9M
Ausgegebene Aktien
94.448.210
Streubesitz (%)
83,41%
Institutioneller Besitz (%)
94,94%
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-1,37
Kurs-Umsatz-Verhältnis (KUV)
0,67
Gewinn pro Aktie (EPS)
-4,29
Beta
1,65

Über Myriad Genetics Inc

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRA... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah. Mehr anzeigen

Sektor
Health Care
Branche
-
Website
Hauptsitz
Salt Lake City, United States
Gegründet
1991
Myriad Genetics Inc is listed in the Health Care sector of the NASDAQ with ticker MYGN. The last closing price for Myriad Genetics was US$6,10. Over the last year, Myriad Genetics shares have traded in a share price range of US$ 3,53 to US$ 8,59.

Myriad Genetics currently has 94.448.210 shares in issue. The market capitalisation of Myriad Genetics is US$550,63 million. Myriad Genetics has a price to earnings ratio (PE ratio) of -1.37.

MYGN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.15-2.508361204015.986.2555.71511278825.9501583CS
41.225.91792656594.636.2554.1916458625.35753398CS
120.6913.42412451365.146.2553.5316821904.59119121CS
26-0.795-126.6257.153.5316673784.74339212CS
520.122.101576182145.718.593.5315227165.54415597CS
156-16.91-74.3623570822.7429.33.53114535710.72421904CS
260-27.51-82.513497300533.3436.95473.5391409013.89216611CS

MYGN - Frequently Asked Questions (FAQ)

What is the current Myriad Genetics Inc share price?
The current share price of Myriad Genetics Inc is US$ 5,83
How many Myriad Genetics Inc shares are in issue?
Myriad Genetics Inc has 94.448.210 shares in issue
What is the market cap of Myriad Genetics Inc?
The market capitalisation of Myriad Genetics Inc is USD 550,63M
What is the 1 year trading range for Myriad Genetics Inc share price?
Myriad Genetics Inc has traded in the range of US$ 3,53 to US$ 8,59 during the past year
What is the PE ratio of Myriad Genetics Inc?
The price to earnings ratio of Myriad Genetics Inc is -1,37
What is the cash to sales ratio of Myriad Genetics Inc?
The cash to sales ratio of Myriad Genetics Inc is 0,67
What is the registered address of Myriad Genetics Inc?
The registered address for Myriad Genetics Inc is 322 North 2200 West, Salt Lake City, Utah, 84116
What is the Myriad Genetics Inc website address?
The website address for Myriad Genetics Inc is www.myriad.com

MYGN Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen